FULC 2.99 (-0.66%)
US3596161097BiotechnologyBiotechnology

Fulcrum Therapeutics (FULC) Stock Highlights

2.99 | -0.66%
2024-11-21 05:21:28
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

Statistics

Range Today
2.95 3.06
Volume Today 782.4K
Range 1 Year
2.86 13.7
Volume 1 Year 241.57M
Range 3 Year
2.25 24.79
Volume 3 Year 684.76M
Range 10 Year
2.25 33.1
Volume 10 Year 982.96M

Highlights

Market Capitalization 217.78M (small)
Floating Shares 40.45M
Current Price 2.99
Price To Earnings -10.29
Price To Revenue -0.57
Price To Book 0.79
Earnings Per Share -0.34
Payout Ratio 0%

Performance

Latest -0.66%
1 Month -15.06%
3 Months -67.81%
6 Months -61.47%
1 Year -27.95%
3 Years -82.65%
5 Years -70.94%
10 Years -79.38%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.